Alloplex’s founder and CEO, Dr. Frank Borriello, will be attending the upcoming LSX Leaders Congress in Boston on September 13 and 14 at the Hynes Convention Centre.
Alloplex is seeking strategic partners and investors to support a de-risked Phase 2 ready clinical stage cellular therapy opportunity with highly differentiated features and exceptionally broad promise across solid tumors.
SUPLEXA cells are an autologous, non-engineered therapy comprised of highly activated immune cells. They have already demonstrated a pristine safety profile and single-agent activity in end-stage solid cancer patients who have failed multiple lines of prior therapy, including chemotherapy as well as immune checkpoint inhibitors (ICIs).
SUPLEXA cells act by several mechanisms of action, including direct tumor killing, activating host T cells and altering the host immune system bias favoring anti-tumor response. The mechanisms perfectly complement those of ICIs and thereby delineate a clear clinical development path toward registration.
The SUPLEXA cells represent a unique, and potentially highly disruptive, therapeutic platform with a proven simple, robust and reproducible manufacturing procedure. It is protected by a combination of issued patents and trade secrets to ensure maximum protection.
To schedule a 1:1 meeting with Dr. Borriello at the upcoming LSX Leaders Congress, please use the conference partnering system, otherwise email firstname.lastname@example.org for a meeting request outside of the conference dates.